Live in the NASDAQ market site in the heart of New York City's Times Square

This is Fast Money. Here's what's on tap tonight. Drugs on demand Eli Lillie

to bypass the pharma Middleman and go direct to consumers with its new obesity drug Zetbound. Is this all

about simplifying access to this blockbuster category or a real industry game changer?

We'll debate that.

Plus, Burger Blues, McDonald's issuing a warning about the impact the war in Israel and the unrest

in the Middle East is having on its business.

While others soon be raising similar red flags, and later one top tech watcher has an interesting

buyer for Peloton in the new year.

We'll go inside the Mobile Eye Black Eye.

And thanks to AI, Microsoft is set to kick off a major PC refresh.

We'll explain.

I'm Melissa Lee, coming to you live from studio B.

at the Nasak on the desk tonight. Carter Braxtonworth, Bodwin-Eison, Dan Nathan, and Guyadami.

We start off with Eli Lilly hitting a new all-time high during the session before closing the day with a slight

loss shares jumping as much as 3% at their highs. The stock is up nearly 70% in the

last year. Today's action coming after the Lily announced the launch of

Lily Direct, a direct to consumer

website that allows patients to order its weight loss drug Zepbound right from the company.

It is a strategy that could deal a blow to traditional pharmacy companies like CBS and Walgreens.

Shares of Novo Nordisk, which manufacturers' rival with Govi, held on to its gains,

jumping almost 4%, closing at a record.

...